13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00501696
(ClinicalTrials.gov)
February 200712/7/2007A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose NaltrexoneA Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54)Multiple SclerosisDrug: 4.5 mg Naltrexone;Drug: NaltrexoneUniversity of California, San FranciscoNULLCompleted18 Years86 YearsBoth80Phase 3United States
2EUCTR2005-005679-13-IT
(EUCTR)
28/06/200623/06/2006An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - NDAn open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - ND multiple sclerosis
MedDRA version: 6.1;Level: PT;Classification code 10053395
INN or Proposed INN: NaltrexoneOSPEDALE S. RAFFAELENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Italy